# An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

> **NCT02413489** · PHASE2 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 36 (actual)

## Conditions studied

- Lymphoma, Mantle-Cell
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, Follicular

## Interventions

- **DRUG:** Daratumumab

## Key facts

- **NCT ID:** NCT02413489
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-02
- **Primary completion:** 2017-06-01
- **Final completion:** 2017-06-01
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL cohort was terminated due to slow recruitment and aggressive disease.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02413489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02413489, "An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02413489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*